35920-39-9 Usage
Chemical Properties
White Solid
Uses
Different sources of media describe the Uses of 35920-39-9 differently. You can refer to the following data:
1. A potent adenosine receptor agonist. Inhibits platelet aggregation and is centrally active in vivo
2. Potent adenosine receptor agonist with some affinity at A1 and A2 receptors
3. 5′-(N-Ethylcarboxamido)adenosine has been used:for the purification of human adenosine A2Areceptor (A2AR) in decylmaltoside (DM)to determine nonspecific binding of adenosine receptorsto investigate adenosine 2B receptor (RA2B) mechanism of action by competition assay
Definition
ChEBI: A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by an N-ethylcarboxamido group.
General Description
A cell-permeable adenosine analog that acts a potent non-selective agonist of adenosine receptors (Ki = 14 nM, 20 nM, 2.4 μM and 6.2 nM for A1, A2A, A2B, A3, respectively). Increases intracellular cAMP production (EC50 = 3.1 μM in A2B expressing CHO cells). Shown to increase glucagon release in a dose-dependent manner and inhibit insulin release at low concentrations. Although at higher concentration some insulin release is observed. Also, displays a wide range adenosine-dependent effects, such as blocking platelet aggregation and inhibiting DNA synthesis. When administered at reperfusion, it is shown reduce infarction and block the formation of the mitochondrial permeability transition pore by activating p70S6 kinase.
Biological Activity
Potent adenosine receptor agonist (K i values are 14, 20 and 6.2 nM for human A 1 , A 2A and A 3 receptors respectively; EC 50 = 2.4 μ M for human A 2B ). Inhibits platelet aggregation and is centrally active in vivo .
Biochem/physiol Actions
Reversible: yes
Check Digit Verification of cas no
The CAS Registry Mumber 35920-39-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,5,9,2 and 0 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 35920-39:
(7*3)+(6*5)+(5*9)+(4*2)+(3*0)+(2*3)+(1*9)=119
119 % 10 = 9
So 35920-39-9 is a valid CAS Registry Number.
35920-39-9Relevant articles and documents
Ring opening reactions: Synthesis of AICAR analogs as potential antimetabolite agents
Costanzi,Lambertucci,Portino,Volpini,Vittori,Cristalli
, p. 415 - 418 (2008/02/01)
In an attempt to improve the A2A selectivity of the 2-(aryl)alkylthio derivatives of adenosine, we planned the synthesis of the corresponding derivatives of the 5′-N-ethylcarboxamidoadenosine (NECA). For this purpose, we designed the synthesis of 2-mercapto-NECA to be pursued by means of an opening-closure method. We obtained the open AICAR analog; however, ring closure efforts failed to give the desired compound. The newly synthesized AICAR derivative could potentially be endowed with antiviral or antitumoral activity. Copyright Taylor & Francis, Inc.
N6-substituted N-alkyladenosine-5'-uronamides: bifunctional ligands having recognition groups for A1 and A2 adenosine receptors.
Olsson,Kusachi,Thompson,Ukena,Padgett,Daly
, p. 1683 - 1689 (2007/10/02)
The coronary vasoactivity of N-ethyl-1'-deoxy-1'-(6-amino-9H-purin-9-yl)-beta-D-ribofuranuronamide (NECA, 1) is over 2 orders of magnitude greater than that of adenosine, and the vasoactivity of certain N6-substituted adenosines is as much as 1 order of m
Adenosine-5'-carboxylic acid amides
-
, (2008/06/13)
Adenosine-5'-carboxylic acid amides represented by the formula STR1 wherein R1 and R2 are each selected from the group consisting of hydrogen, loweralkyl, lowerhaloalkyl, lowerhydroxyalkyl, lowercycloalkyl, loweralkylcycloalkyl, loweralkenyl, lowerhaloalkenyl, lowerhydroxyalkenyl, loweralkynyl, lowerhaloalkynyl, benzylamino, phenyl, loweralkylphenyl, loweralkoxyloweralkyl, substituted phenyl, 2-methylfuran or di(C1 -C4)alkylamino(C1 -C4)alkyl, adamantyl or R1 and R2 taken together form a 5 or 6 membered heterocyclic moiety; R3 and R4 are hydrogen or acyl, or taken together form an isopropylidene or a benzylidene group; or a pharmaceutically acceptable acid addition salt thereof.
